A PYMNTS Company

India: Sun-Ranbaxy $4-billion merger gets high court approval

By  |  March 9, 2015

The $4-billion merger between Sun Pharmaceutical Industries and Ranbaxy Laboratories has crossed the final hurdle, with the Punjab & Haryana High Court giving approval.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Once the deal closes, expected this month, Sun will become the world’s fifth largest generic drug maker.

    On January 31, the US Federal Trade Commission cleared the merger, following the Competition Commission of India’s (CCI) conditional nod. CCI has asked both companies to divest seven drug assets in India as a pre-requisite.

    With this, brand Sun is ready to take charge, as Ranbaxy would fade away eventually in India.

     

    Full Content: Business Standard

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.